Sage Journals: Discover world-class research

Abstract

Antiangiogenic and antilymphangiogenic gene therapy with soluble vascular endothelial growth factor receptor-2 (VEGFR-2) and soluble VEGFR-3 in combination with chemotherapy is a potential new treatment for ovarian carcinoma. We evaluated the safety, toxicology, and biodistribution of intravenous AdsVEGFR-2 and AdsVEGFR-3 combined with chemotherapy in healthy rats (n=90) before entering a clinical setting. The study groups were: AdLacZ and AdLacZ with chemotherapy as control groups, low dose AdsVEGFR-2 and AdsVEGFR-3, high dose AdsVEGFR-2 and AdsVEGFR-3, combination of low dose AdsVEGFR-2 and AdsVEGFR-3 with chemotherapy, combination of high dose AdsVEGFR-2 and AdVEGFR-3 with chemotherapy, and chemotherapy only. The follow-up time was 4 weeks. Safety and toxicology were assessed by monitoring the clinical status of the animals and by histological, hematological, and clinical chemistry parameters. For the biodistribution studies, quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA) were used.

Low dose (2×10¹⁰ vp) AdsVEGFR-2 and AdsVEGFR-3 gene therapy was well tolerated, even when gene therapy was combined with chemotherapy. Notably, only transient elevation of liver enzymes and mild regenerative changes were seen in liver after the gene transfer in the groups that received high doses (2×10¹¹ vp) of AdsVEGFR-2 and AdsVEGFR-3 with or without chemotherapy. No life-threatening adverse effects were noticed in any of the treatment groups. The highest protein concentration of soluble VEGFR-2 (sVEGFR-2) in circulation was seen 1 week after the gene transfer. The combination of chemotherapy to gene therapy seemed to prolong the time of detectable transgene protein at least 1 week in the circulation. The expression of AdsVEGFR-2 and AdsVEGFR-3 transgenes was mainly seen in the liver and spleen as detected by qRT-PCR. According to these results, AdsVEGFR-2 and AdsVEGFR-3 gene therapy combined with chemotherapy is safe and can be brought to clinical testing in ovarian cancer patients.

Tuppurainen and colleagues evaluate the safety, toxicology, and biodistribution of intravenously administered adenovirus harboring soluble vascular endothelial growth factor receptor (VEGF)-2 and -3 in combination with chemotherapy in healthy rats. Low-dose gene therapy was well tolerated even when combined with chemotherapy, and only transient elevation of liver enzymes was seen in groups receiving high doses. Combination treatments also prolonged detectable transgene protein in circulation by about 1 week.

Get full access to this article

View all access options for this article.

References

Achen

M.G.

, Jeltsch

, Kukk

et al. 1998. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) Proc. Natl. Acad. Sci. U.S.A., 95:548–553.

Alvarez

R.D.

, Gomez-Navarro

, Wang

et al. 2000. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther., 2:524–530.

Bessis

, Garciacozar

F.J.

, Boissier

M.C.

2004. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther., 11,Suppl 1:S10–17.

Buller

R.E.

, Runnebaum

I.B.

, Karlan

B.Y.

et al. 2002. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther., 9:553–566.

Dixelius

, Makinen

, Wirzenius

et al. 2003. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J. Biol. Chem., 278:40973–40979.

B.A.

, Luck

H.J.

, Meier

et al. 2003. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst., 95:1320–1329.

Folkman

, Shing

1992. Angiogenesis. J. Biol. Chem., 267:10931–10934.

Fong

G.H.

, Klingensmith

, Wood

C.R.

et al. 1996. Regulation of flt-1 expression during mouse embryogenesis suggests a role in the establishment of vascular endothelium. Dev. Dyn., 207:1–10.

Gonin

, Gaillard

2004. Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development. Gene Ther., 11,Suppl 1:S98–S108.

10.

Hanahan

, Weinberg

R.A.

2000. The hallmarks of cancer. Cell., 100:57–70.

11.

Hanker

L.C.

, Loibl

, Burchardi

et al. 2012. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol., 23:2605–2612.

12.

Harlan Laboratories. Harlan datasheet HsdHanWist. 2011.

13.

Hasenburg

, Tong

X.W.

, Rojas-Martinez

et al. 2000. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther., 7:839–844.

14.

Hasenburg

, Tong

X.W.

, Fischer

D.C.

et al. 2001. Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol Oncol., 83:549–554.

15.

, Rajantie

, Pajusola

et al. 2005. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res., 65:4739–4746.

16.

Heintz

A.P.

, Odicino

, Maisonneuve

et al. 2006. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynaecol. Obstet., 95,Suppl 1:S161–S192.

17.

Jemal

, Bray

, Center

M.M.

et al. 2011. Global cancer statistics. CA Cancer J. Clin., 61:69–90.

18.

Joukov

, Pajusola

, Kaipainen

et al. 1996. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J., 15:290–298.

19.

Kendall

R.L.

, Thomas

K.A.

1993. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. U.S.A., 90:10705–10709.

20.

Laakkonen

, Waltari

, Holopainen

et al. 2007. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res., 67:593–599.

21.

Langford

, Dayan

, Yla-Herttuala

, Eckland

2009. A preclinical assessment of the safety and biodistribution of an adenoviral vector containing the herpes simplex virus thymidine kinase gene (Cerepro) after intracerebral administration. J. Gene Med., 11:468–476.

22.

, Liu

, Li

et al. 2009. Vascular endothelial growth factor D and intratumoral lymphatics as independent prognostic factors in epithelial ovarian carcinoma. Anat. Rec. (Hoboken), 292:562–569.

23.

Nishida

, Yano

, Komai

et al. 2004. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer, 101:1364–1374.

24.

Olsson

A.K.

, Dimberg

, Kreuger

, Claesson-Welsh

2006. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol., 7:359–371.

25.

Sallinen

, Anttila

, Närväinen

et al. 2006. A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up. Gynecol. Oncol., 103:315–320.

26.

Sallinen

, Anttila

, Närväinen

et al. 2009. Antiangiogenic gene therapy with soluble VEGFR-1, −2, and −3 reduces the growth of solid human ovarian carcinoma in mice. Mol. Ther., 17:278–284.

27.

Shen

G.H.

, Ghazizadeh

, Kawanami

et al. 2000. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br. J. Cancer., 83:196–203.

28.

Shibuya

2006a. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis, 9:225–230; discussion 231.

29.

Shibuya

2006b. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J. Biochem. Mol. Biol., 39:469–478.

30.

Shibuya

, Yamaguchi

, Yamane

et al. 1990. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene., 5:519–524.

31.

Sinn

B.V.

, Rb-Esfahani

, Wirtz

R.M.

et al. 2009. Vascular endothelial growth factor C mRNA expression is a prognostic factor in epithelial ovarian cancer as detected by kinetic RT-PCR in formalin-fixed paraffin-embedded tissue. Virchows Arch., 455:461–467.

32.

Sopo

, Anttila

, Sallinen

et al. 2012. Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma. Int. J. Cancer., 131:2394–2401.

33.

Stone

, Liu

, Shayakhmetov

et al. 2007. Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J. Virol., 81:4866–4871.

34.

Takayama

, Ueno

, Nakanishi

et al. 2000. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res., 60:2169–2177.

35.

Tao

, Gao

G.P.

, Parr

et al. 2001. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol. Ther., 3:28–35.

36.

Teoh

, Secord

A.A.

2012. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer. Int. J. Gynecol. Cancer., 22:348–359.

37.

Tolcher

A.W.

, Hao

, De Bono

et al. 2006. Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. J. Clin. Oncol., 24:2052–2058.

38.

Tucker

M.J.

1997. Diseases of the Wistar Rat. CRC Press: Boca Raton, FL, 9–14.

39.

Valtola

, Salven

, Heikkilä

et al. 1999. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am. J. Pathol., 154:1381–1390.

40.

Wei

, Kuhnert

, Kuo

C.J.

2008. Recombinant adenovirus as a methodology for exploration of physiologic functions of growth factor pathways. J. Mol. Med. (Berl)., 86:161–169.

41.

Yamamoto

, Konishi

, Mandai

et al. 1997. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br. J. Cancer., 76:1221–1227.

42.

Yang

, Nunes

F.A.

, Berencsi

et al. 1994. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U.S.A., 91:4407–4411.

43.

Yokoyama

, Charnock-Jones

D.S.

, Licence

et al. 2003. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br. J. Cancer., 88:237–244.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.14 MB

Preclinical Safety,Toxicology,and Biodistribution Study of Adenoviral Gene Therapy with sVEGFR-2 and sVEGFR-3 Combined with Chemotherapy for Ovarian Cancer

Abstract

Get full access to this article

References

Supplementary Material